Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

Can This Red-Hot Biotech Stock Live Up to Wall Street’s Expectations?

  • Adaptive Biotechnologies (ADPT) is a commercial-stage biotech with strong technical momentum.
  • Shares are up 250% in the past year and just hit a new three-year high.
  • ADPT maintains a 100% “Buy” opinion from Barchart, a Trend Seeker “Buy” signal, and robust technical indicators.
  • Fundamentals show projected revenue and earnings growth, but the company struggles with profitability and exhibits high volatility.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.